In English, it would be: Kangtai Pharmaceutical-B (09939.HK): Clinical observation results show that the combination therapy of KX-826 and minoxidil is significantly better than minoxidil alone in treating androgenic alopecia in adult Chinese males.

Zhijing Financial News APP news, Kotler Pharmaceuticals-B (09939.HK) issued an announcement regarding the Phase Ib/III clinical trial of KX-826 in combination with minoxidil for the treatment of androgenetic alopecia (AGA or hair loss) in adult male Chinese. The clinical trial aims to evaluate the effectiveness and safety of KX-826 in combination with minoxidil for the treatment of hair loss in adult Chinese males. In order to obtain predictions of efficacy, dosage, and patient numbers before conducting a larger Phase III clinical trial, the company initiated a clinical observation trial for the combination treatment of KX-826 and minoxidil in adult Chinese males with hair loss in March 2024, in collaboration with two domestic hospitals.